Page 44 - Ovarian Cancer Surgery - Quality Indicators

exploratory analysis of the AGO-OVAR
Arbeitsgemeinschaft Gynaekologische
Onkologie Ovarian Cancer Study Group.
Ann Surg Oncol 17, 1642-1648 2010.
164. Chang, S.J., Bristow, R.E. & Ryu, H.S.
Prognostic significance of systematic
lymphadenectomy as part of primary
debulking surgery in patients with
advanced ovarian cancer. Gynecol Oncol
126, 381-386 2012.
165. du Bois, A., et al. Role of surgical
outcome as prognostic factor in advanced
epithelial ovarian cancer: a combined
exploratory analysis of 3 prospectively
randomized phase 3 multicenter trials: by
the Arbeitsgemeinschaft Gynaekologische
Onkologie Studiengruppe
Ovarialkarzinom AGO -OVAR and the
Groupe d'Investigateurs Nationaux Pour
les Etudes des Cancers de l'Ovaire
GINECO). Cancer 115, 1234-1244
2009.
166. Cai, H.B., Zhou, Y.F., Chen, H.Z. & Hou,
H.Y. The role of bowel surgery with
cytoreduction for epithelial ovarian cancer.
Clin Oncol R Coll Radiol) 19, 757-762
2007.
167. Fu, Y., Wang, X., Pan, Z. & Xie, X.
Clinical outcomes and prognostic factors
of patients with epithelial ovarian cancer
subjected to first-line treatment: a
retrospective study of 251 cases. Front
Med 8, 91-95 2014.
168. Gerestein, C.G., et al. The prediction of
progression-free and overall survival in
women with an advanced stage of
epithelial ovarian carcinoma. BJOG 116,
372-380 2009.
169. Kaern, J., et al. Prognostic factors in
ovarian carcinoma stage III patients. Can
biomarkers improve the prediction of
short- and long-term survivors? Int J
Gynecol Cancer 15, 1014-1022 2005.
170. Abaid, L.N., et al. The prognostic
significance of optimal debulking in the
setting of a complete clinical response for
advanced ovarian carcinoma patients
 OVARIAN CANCER SURGERY - QUALITY INDICATORS 
44
receiving maintenance chemotherapy.
Arch Gynecol Obstet 283, 1127-1131
2011.
171. Chang, S.J., Bristow, R.E. & Ryu, H.S.
Impact of complete cytoreduction leaving
no gross residual disease associated with
radical cytoreductive surgical procedures
on survival in advanced ovarian cancer.
Ann Surg Oncol 19, 4059-4067 2012.
172. Gadducci, A., et al. Pre-chemotherapy
hemoglobin levels and survival in patients
with advanced epithelial ovarian cancer
who received a first-line taxane/platinum-
based regimen: results of a multicenter
retrospective Italian study. Gynecol Oncol
98, 118-123 2005.
173. Pongsanon, K., Benjapibal, M. &
Ruengkhachorn, I. Prognostic significance
of hemoglobin levels in patients with
primary epithelial ovarian carcinoma
undergoing platinum-based chemotherapy.
Asian Pac J Cancer Prev 12, 131-136
2011.
174. Eisenhauer, E.L., et al. The addition of
extensive upper abdominal surgery to
achieve optimal cytoreduction improves
survival in patients with stages IIIC-IV
epithelial ovarian cancer. Gynecol Oncol
103, 1083-1090 2006.
175. Pecorelli, S., et al. Phase III trial of
observation versus six courses of
paclitaxel in patients with advanced
epithelial ovarian cancer in complete
response after six courses of
paclitaxel/platinum-based chemotherapy:
final results of the After-6 protocol 1. J
Clin Oncol 27, 4642-4648 2009.
176. Everett, E.N., et al. Initial chemotherapy
followed by surgical cytoreduction for the
treatment of stage III/IV epithelial ovarian
cancer. Am J Obstet Gynecol 195, 568-
574; discussion 574-566 2006.
177. Aletti, G.D., Dowdy, S.C., Podratz, K.C.
& Cliby, W.A. Analysis of factors
impacting operability in stage IV ovarian
cancer: rationale use of a triage system.
Gynecol Oncol 105, 84-89 2007.